Related posts

Stock slump continuesEarnings mixed, Powell holds ratesFeds hold rates, markets partially rebound
Investor Insights

This summary was created by AI, based on 37 opinions in the last 12 months.

Pfizer Inc (PFE) is currently seen as a deeply undervalued stock by many analysts, primarily due to its substantial dividend yield of around 6% and low price-to-earnings (P/E) ratio of approximately 10x. The company has faced challenges since the pandemic, with its stock value down significantly from its peak and questions surrounding the success of its recent acquisitions in oncology and other areas. Despite these hurdles, experts anticipate potential for growth driven by a robust R&D pipeline and new product launches, particularly in cancer treatment and weight-loss drugs. While there are concerns about past management decisions and market performance, most analysts believe now could be a strategic entry point for long-term investors looking for income and possible capital appreciation in the future.

Consensus
Hold
Valuation
Undervalued
WATCH

It reports Tuesday. Their anti-cancer drugs still haven't broken up to justify the cost of acquiring them. Good news would pop shares up. Little downside now.

DON'T BUY

It has over paid for some M&A. It is a deep value play but needs a catalyst. It has had some management change but recovery is not part of their investment style. They sold about a year and a half ago.

PAST TOP PICK
(A Top Pick Jan 05/24, Down 5%)

Market's been tough on it. Investing $2B a year on R&D, made some acquisitions. Lots in the pipeline is up in the air. Stock will pop eventually back to its historical $40-45, and then he'll probably cash in. In his income fund, with the yield at 6%.

HOLD

It's too low to sell. Collect the dividend and see if we get good news about the Seagen acquisition.

TOP PICK

If he's right about a correction in 2025, money managers will rotate into defensive areas like staples, utilities, healthcare and REITs. Their chart was in a big downtrend in recent years. PFE's chart has a double bottom this year. Relative strength is moving up. Also, volumes has popped around $25 (trough). The risk/reward is good. You're paid 6.5% to wait, too. $25 is big technical support.

(Analysts’ price target is $32.04)
PAST TOP PICK
(A Top Pick Dec 05/23, Down 8%)

Acquisitions in oncology weren't enough for the stock. A long-term play. Slightly disappointing on the year, but oncology segment will continue to do well going forward.

DON'T BUY

Despite buying a bunch of mega-companies, it remains cheaper than 30 years ago. But it has totally failed to deliver shareholder value. The dividend is safe. 

TOP PICK

Valuation of 10x forward PE. People are missing that they took the windfall from Covid and have redeployed it into acquiring assets, mainly in oncology drugs. We should start to see the growth from that spending in the next couple of years. Could get them to start growing again. Meanwhile, vaccines are still a core position. Yield is 6.5%.

Downside support, upside potential, a bit of earnings growth, low valuation.

(Analysts’ price target is $32.74)
HOLD

A few weeks ago, they reported great earnings, but shares were down because the Covid vaccine drove earnings. Today, shares are down another 5-6%. She added shares a few weeks ago, but is holding now.

TOP PICK

Excellent company with strong pipeline of new projects. Valuation has seen a new low which makes a good time to buy. Vaccine hesitation in new Trump administration not a concern. Dividend very safe - provides margin for investors. 

BUY

Owns share in the income growth fund. Very stable and safe dividend. Current share price is very cheap. Strong R&D pipeline. Expecting company to continue earnings growth. Would recommend buying and holding. 

DON'T BUY

Their success during Covid, with a big sales spike, hurt them after the pandemic. They should be more efficient, namely their return on invested capital. He prefers Merck for its better performance.

DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

With a 5.7% yield, certainly many investors will like what they see as far as income goes from PFE. The company also has a fairly decent history of raising dividends. In 2014 it was 26 cents, it is 42 cents now. As interest rates decline, its dividend may become more attractive to investors. The stock is cheap at 11X earnings, and now up 2% YTD. Our value trap comment mostly refers to lack of growth. EPS this year is expected to be $2.61, not much above the levels of nine years ago and well below the Covid peak (2021). That would not be so bad, if not for the fact that debt has nearly doubled as well in the past 10 years. So there has been no growth but still, financial risks have increased here. 
Unlock Premium - Try 5i Free 

BUY

His pick in the healthcare space. Performance coming into this year not favourable. Value opportunity. Penalized by analysts by lack of takeup in obesity drugs. Buy it for oncology buildout, increased demand there. Solid medium-term outlook.

PARTIAL BUY

Many drugs are moving into phase 3 trials, which could be a catalyst, and trades around a cheap 9x PE. They just finished buying Seagen. They have their own weight-loss drug. The dividend is safe, offers 3-5% consistent growth, plus maybe more growth from their drugs. Are cutting costs the rest of the year.

Showing 1 to 15 of 844 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 12

Bearish - Sell Signals / Votes : 12

Total Signals / Votes : 34

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 34 stock analysts published opinions about PFE-N. 10 analysts recommended to BUY the stock. 12 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

34 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2025-03-14, Pfizer Inc (PFE-N) stock closed at a price of $25.695.